Medical Technology for healthcare professionals
back
Medical Technology

Melding two worlds into one benefit.

ZEISS INTRABEAM 600

  • Local precision
  • Time matters
  • Proven performance

Local precision

The X-ray source (XRS) with different applicator types creates a very focused radiation field. This leads to a targeted local high dose irradiation and enables increased tumor bed sterilization.1 A very low radiation scattering spares healthy structures and organs at risk from radiation reducing unwanted side-effects2 in contrary to conventional treatment workflows.

Precision and immediacy - one step ahead with IORT during tumor resection

Treatment versatility with our different types of INTRABEAM® Applicators from ZEISS

ZEISS INTRABEAM Spherical Applicator

The ZEISS INTRABEAM Spherical Applicator can be used for the intracavitary intraoperative delivery of radiation to the tumor bed, e.g. at the time of breast conserving surgery.

ZEISS INTRABEAM Needle Applicator

The ZEISS INTRABEAM Needle Applicator can be used for the interstitial irradiation of tumors, e.g. in the treatment of vertebral metastases or brain tumors.

ZEISS INTRABEAM Flat Applicator

The ZEISS INTRABEAM Flat Applicator can be used for the treatment of the tumor bed on surgically exposed surfaces, e.g. tumors of the gastrointestinal tract.

ZEISS INTRABEAM Surface Applicator

The ZEISS INTRABEAM Surface Applicator can be used in the treatment of the tumor bed on the surface of the body, for example, irradiation of non-melanoma skin cancers.

Time matters

Immediate irradiation during surgery in the OR prevents tumor reformation stimulated by wound healing after resection3,4 and can lead to shorter overall treatments. This efficiently saves hospital time without compromising outcomes and lets patients benefit from a completed treatment while sleeping.5

Shorter overall treatments

Post-operative treatment times of up to 6.5 weeks can be reduced to 3-5 weeks or even be eliminated for selected patients when adding IORT during breast-conserving surgery (BCS).2

Proven performance

ZEISS INTRABEAM devices have an extensive record of +250 peer-reviewed publications and +20 studies from over 30 countries confirming the clinical value of personalized and patient-centric IORT treatment options. This helps you to meet future clinical demands and secure reimbursements – a primary aspect of successful healthcare management in the future.

Learn more about study and treatment activities of your peers worldwide

  • Countries (dark grey) where INTRABEAM® devices are already used.

  • Author
    Title
    Details
    Scope
    Reference
    Kalapurakal, J.A., et al.
    Northwestern Memorial Hospital, Chicago, USA
    Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors
    Clinical outcomes of IORT after maximal tumor resection showed no irreversible grade 3 or higher toxicity in patients.
    Evidence: Level 2
    No. of patients: 11
    Median follow-up: 33.0 months
    No. of centers: 1
    Kalapurakal, J.A., et al. (2010). Final Results of a Phase I Dose Escalation Study of Intraoperative Radiation Therapy in Children with Radiation Recurrent Posterior Fossa Tumors. Radiation Oncology, 78(3) Supplement, 19-20
    Weil, R.J., et al.
    Cleveland Clinic, Cleveland, USA
    Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes
    Clinical outcomes for IORT with INTRABEAM® to the cavity during brain metastasis resection show comparable results for local and distant control and long-term survival compared to conventional teatment modalities.
    Evidence: Level 2
    No. of patients: 23
    Median follow-up: 22.0 months
    No. of centers: 1
    Weil, R. J., et al. (2015). Intraoperative radiotherapy to treat newly diagnosed solitary brain metastasis: initial experience and long-term outcomes, Journal of Neurosurgery JNS, 122(4), 825-832
    Cifarelli, C., et al.
    West Virginia University Hospital, Morgantown, USA
    Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study
    Evidence: Level 2
    No. of patients: 54
    Median follow-up: 7.2 months
    No. of centers: 3
    Cifarelli, C.P., et al. (2019). Intraoperative radiotherapy (IORT) for surgically resected brain metastases: outcome analysis of an international cooperative study. J Neurooncol 145, 391 397. https://doi:10.1007/s11060-019-03309-6
    Also in Morgantown - Vargo, J.A., et al. (2018) investigating the feasibility of dose escalation for IORT vs. SRS during brain metastases resection.
    Ghaly, M., et al.
    Northwell Health, New York, USA
    Kypho-Intra Operative Radiation Therapy (IORT) for Localized Spine Metastasis, Phase I/II Study
    Evaluation of response rate of pain control of Kypho-IORT, feasibility, tolerability (side effects) within 90 days post-procedure, determination of clinical factors for vertebral compression fracture.
    Evidence: Level 2
    No. of patients: 22 planned
    No. of centers: 1
    Clinical Trial Identifier: NCT02987153
  • Author
    Title
    Details
    Scope
    Reference
    Giordano, F., et al.
    University Medical Center Mannheim, Mannheim, Germany
    A Multicenter Randomized Phase III Trial on INTraoperative RAdiotherapy in Newly Diagnosed GliOblastoma Multiforme (INTRAGO II)
    Evidence: Level 1
    No. of patients: 314 planned
    No. of centers: 20 planned
    Clinical Trial Identifier: NCT02685605
    Other Level 1 & 2 studies in Mannheim - INTRAGO I (Brain), a pooled analysis (Brain), TARGIT-E (Breast) and Kypho-IORT (Spine)
    Vaidya, J., et al.
    University College London, London, UK
    Long-term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial
    Clinical outcomes show local recurrence of IORT is non-inferior to EBRT and significantly fewer non-breast-cancer deaths compared to EBRT.
    Evidence: Level 1
    No. of patients: 2298
    Median follow-up: 102.0 months
    No. of centers: 32
    Vaidya, J. S. et al. (2020). Long-term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, 370, m2836. https://doi.org/10.1136/bmj.m2836
    Also active in London - Vaidya, J., et al., with TARGIT-B comparing IORT Boost with EBRT Boost in early-stage breast cancer, 1790 patients in 35 centers planned (Clinical Trial Identifier: NCT01792726)
    Le Blanc, M., et al.
    Institut De Cancérologie De L'Ouest - Nantes, Nantes, France
    Medico Economic Study, Randomized, Comparing Intraoperative Radiotherapy With Intrabeam® on Surgical Resection Bed Versus Conventional Surgery + EBRT in Postmenopausal Patients Operated by Conservative Surgery for Low Risk Breast Cancer

    Comparison of IORT with INTRABEAM® versus EBRT, in terms of costs, local-regional survival without recurrence, rate of early and late complications, impact aesthetic outcome and quality of life of patients.

    Evidence: Level 1
    No. of patients: 246
    No. of centers: 9
    Clinical Trial Identifier: NCT03637738
  • Author
    Title
    Details
    Scope
    Reference
    Wang, M., et al.
    Second Hospital of Jilin University, Changchun, China
    Single Center Study of Intraoperative Radiotherapy for Middle and Low Rectal Cancer in the Standard of Peritoneal Inversion Rectal Cancer
    Assessment of post-op acute complication and short-term acute efficacy for patients with middle and low rectal cancer treated with IORT after intersphincteric resection.
    Evidence: Level 1
    No. of patients: 50
    No. of centers: 1
    Clinical Trial Identifier: NCT03209336
    Ning, L., et al.
    Guangdong Academy of Medical Sciences, Guanzhou, China
    Intra-operative Radiotherapy After Breast-conserving Surgery in Treating Women With Ductal Carcinoma in Situ Breast Cancer
    Effectiveness measurement of intraoperatve radiotherapy (IORT) during breast-conserving surgery for low grade ductal carcinoma in situ breast cancer.
    Evidence: Level 1
    No. of patients: 222
    No. of centers: 1
    Clinical Trial Identifier: NCT02389673
    Lee, I.J., et al.
    Gangnam Severance Hospital, Seoul, South Korea
    A Prospective, Phase II Study Investigating Efficacy of Intraoperative Radiation Therapy for Resectable Pancreatic Cancer
    Investigation of IORT efficacy resectable pancreatic adenocarcinoma patients with regards to local recurrence rate after surgical resection with and without IORT.
    Evidence: Level 2
    No. of patients: 42 planned
    No. of centers: 1
    Clinical Trial Identifier: NCT03273374

Stay updated with the latest news on
ZEISS INTRABEAM 600

If you want to have more information on data processing at ZEISS please refer to our data privacy notice.

Supporting a broad set of oncological indications

ZEISS INTRABEAM 600 enables targeted irradiation of various tumor types

  • Brain tumors

  • Spinal metastases

  • Breast cancer

  • Gastrointestinal tumors

  • Head & neck tumors

  • Skin cancer

Peer-to-peer experiences of IORT in the OR using INTRABEAM from ZEISS

Watch clinical live-cases of brain, spine and breast indications performed by clinical experts.

  • Brain Metastases

  • Breast Cancer

  • Spinal Metastases

Downloads

  • INTRABEAM 600 Technical Specifications EN

    Pages: 24
    File size: 1 MB
  • 1

    Vargo, J. A., et al. (2018). Feasibility of dose escalation using intraoperative radiotherapy following resection of large brain metastases compared to post-operative stereotactic radiosurgery. Journal of Neuro-Oncology, 140(2), 413–420.

  • 2

    Vaidya, J. S. et al. (2020). Long-term survival and local control outcomes from single dose targeted intraoperative radiotherapy during lumpectomy (TARGIT-IORT) for early breast cancer: TARGIT-A randomised clinical trial. BMJ, 370, m2836. https://doi.org/10.1136/bmj.m2836

  • 3

    Belletti, B., et al. (2008). Targeted Intraoperative Radiotherapy Impairs the Stimulation of Breast Cancer Cell Proliferation and Invasion Caused by Surgical Wounding. Clinical Cancer Research, 14(5), 1325–1332.

  • 4

    Fabris, L., et al. (2016). Radiotherapy-induced miR-223 prevents relapse of breast cancer by targeting the EGF pathway. Oncogene, (November 2015), 1–13.

  • 5

    Welzel, G., et al. (2013). Radiation-related quality of life parameters after targeted intraoperative radiotherapy versus whole breast radiotherapy in patients with breast cancer: results from the randomised phase III trial TARGIT-A. Radiation Oncology, 8(1), 9.